Quick Take
Greenwich LifeSciences (GLSI) has filed to raise $23.5 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing an immunotherapy designed to prevent the recurrence of breast cancer.
GLSI is preparing to enter Phase 3 trials in 2020 for its sole candidate.
I’ll provide a final opinion when we learn management’s pricing and valuation assumptions for the IPO.
Company & Technology
Stafford, Texas-based Greenwich was founded to develop an adjuvant therapy for patients with HER2/neu 3+ breast cancer in conjunction with Herceptin.
Management